Apr 6, 2022 | News
Calgary, Alberta, Canada, April 6, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that has initiated its pre-clinical oral formulation...
Mar 30, 2022 | News
Calgary, Alberta – March 30, 2022 – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”) today announced its financial results for the second quarter ended January 31, 2022. For...
Feb 16, 2022 | News
Calgary, Alberta–(Newsfile Corp. – February 15, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to report the proxy...
Feb 8, 2022 | News
Calgary, Alberta–(Newsfile Corp. – February 8, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”) is pleased to provide a...
Feb 1, 2022 | News
Calgary, Alberta–(Newsfile Corp. – February 1, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) (“Marvel” or the “Company”) is pleased to announce the appointment of Harry Nijjar, CPA, CMA, as Chief Financial Officer of the...
Dec 16, 2021 | News
Calgary, Alberta–(Newsfile Corp. – December 16, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces it has successfully...
